JNJ-Q2: Difference between revisions
Content deleted Content added
Anypodetos (talk | contribs) |
Update on testing |
||
| Line 44: | Line 44: | ||
Furiex Pharmaceuticals has licensed JNJ-Q2 from [[Janssen Pharmaceutica]], a unit of [[Johnson & Johnson]], which discovered JNJ-Q2. Furiex is responsible for its development and commercialization. Both oral and intravenous formulations are being developed.<ref>{{cite web |title=Novel Fluoroquinolone (JNJ-Q2) |publisher=Furiex Pharmaceuticals |url=http://www.furiex.com/pipeline/discoverydevelopment-pipeline/fluoroquinolone/}}</ref> |
Furiex Pharmaceuticals has licensed JNJ-Q2 from [[Janssen Pharmaceutica]], a unit of [[Johnson & Johnson]], which discovered JNJ-Q2. Furiex is responsible for its development and commercialization. Both oral and intravenous formulations are being developed.<ref>{{cite web |title=Novel Fluoroquinolone (JNJ-Q2) |publisher=Furiex Pharmaceuticals |url=http://www.furiex.com/pipeline/discoverydevelopment-pipeline/fluoroquinolone/}}</ref> |
||
As of 2016, tests are ongoing, though they appear to be positive<ref>{{Cite journal|last=Jones|first=Travis M.|last2=Johnson|first2=Steven W.|last3=DiMondi|first3=V. Paul|last4=Wilson|first4=Dustin T.|date=2016|title=Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections|url=https://www.ncbi.nlm.nih.gov/pubmed/27354817|journal=Infection and Drug Resistance|volume=9|pages=119–128|doi=10.2147/IDR.S105620|issn=1178-6973|pmc=4908938|pmid=27354817}}</ref>. |
|||
==References== |
==References== |
||
Revision as of 05:54, 16 March 2020
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral, IV |
| Identifiers | |
| |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H23F2N3O4 |
| Molar mass | 419.42 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
JNJ-Q2 is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia. Specifically, JNJ-Q2 is being actively studied for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections.[2][3]
Furiex Pharmaceuticals has licensed JNJ-Q2 from Janssen Pharmaceutica, a unit of Johnson & Johnson, which discovered JNJ-Q2. Furiex is responsible for its development and commercialization. Both oral and intravenous formulations are being developed.[4]
As of 2016, tests are ongoing, though they appear to be positive[5].
References
- ^ "CSID:9721013". ChemSpider. Retrieved Aug 30, 2012.
- ^ Farrell DJ, Liverman LC, Biedenbach DJ, Jones RN (July 2011). "JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains". Antimicrob. Agents Chemother. 55 (7): 3631–4. doi:10.1128/AAC.00162-11. PMC 3122438. PMID 21555765.
- ^ Morrow BJ, He W, Amsler KM, et al. (May 2010). "In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone". Antimicrob. Agents Chemother. 54 (5): 1955–64. doi:10.1128/AAC.01374-09. PMC 2863672. PMID 20176911.
- ^ "Novel Fluoroquinolone (JNJ-Q2)". Furiex Pharmaceuticals.
- ^ Jones, Travis M.; Johnson, Steven W.; DiMondi, V. Paul; Wilson, Dustin T. (2016). "Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections". Infection and Drug Resistance. 9: 119–128. doi:10.2147/IDR.S105620. ISSN 1178-6973. PMC 4908938. PMID 27354817.
{{cite journal}}: CS1 maint: unflagged free DOI (link)
 | This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |